human
-
Huntexil update: EMA asks for further trial
European Medicines Agency (EMA) tells NeuroSearch a European license for Huntexil in HD requires another large trial
-
Improving Huntington's disease clinical trial recruitment through patient and family education
How can we improve recruitment into Huntington's disease clinical trials? Talking directly with families works!
-
The genetic 'gray area' of Huntington's disease: what does it all mean?
Intermediate alleles and reduced penetrance – the genetic 'gray area' of Huntington’s disease, explained
-
Dimebon fails in late-stage human HD clinical trial
Dimebon fails to improve symptoms in HD patients in the HORIZON trial
-
FDA: further trial needed for Huntexil approval in HD
Bad news for Huntexil – the FDA requires another trial before it can be approved in the US
-
Successful gene therapy trial in Parkinson’s Disease gives hope for HD
Success for brain ‘gene therapy’ in Parkinson’s disease – good news for similar treatments being developed in HD
-
An active lifestyle may make a difference to HD symptoms
More reasons to be active: a passive lifestyle may contribute to earlier onset of symptoms in HD.
-
Dimebon: disappointing in Alzheimer’s but might work in HD
Dimebon – disappointing results in an Alzheimer’s disease trial, but hope remains for HD.
-
Does HD cause brains to develop differently?
Smaller total brain volumes in male HD mutation carriers suggests brain development may be different in HD.
-
Huntexil for symptoms of Huntington's disease: where are we now?
Two clinical trials in Europe and the USA have suggested a new drug, Huntexil, might improve movements in HD. The nex